Research
Hormonal
Resmetirom is a recommended pharmacotherapy for adults with non-cirrhotic MASH and significant liver fibrosis (stage ≥2), demonstrating histological effectiveness on steatohepatitis and fibrosis.
If you have advanced liver scarring (fibrosis stage 2 or higher) but not cirrhosis, ask your doctor about resmetirom, a medication that can improve liver health.
WeakSupportsHIGH confidence
If locally approved and dependent on the label, adults with non-cirrhotic MASH and significant liver fibrosis (stage ≥2) should be considered for a MASH-targeted treatment with resmetirom, which demonstrated histological effectiveness on steatohepatitis and fibrosis with an acceptable safety and tolerability profile.
Why this rating
Based on clinical trials demonstrating histological effectiveness.
Source
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Frank Tacke et al. · Obesity Facts · 2024
DOI 10.1159/000539371
clinical_guidelineCited 385×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle modification, specifically weight loss, dietary changes, and physical exercise, is the foundational treatment for adults with MASLD, alongside optimal management of comorbidities.Weak
- Incretin-based therapies (e.g., semaglutide, tirzepatide) are advised for the optimal management of comorbidities like type 2 diabetes or obesity in adults with MASLD.Weak
- Bariatric surgery is an option for individuals with MASLD and obesity.Weak
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →